Pharmaceuticals, Biotechnology and Life Sciences
Certara is applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19.
Bristol Myers Squibb has reported first quarter revenues of $10.8 Billion, an increase of 82%, on a pro forma basis, revenue increase of 13% or 8% excluding impact of COVID-19.
Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round.
Ironwood has increased total revenue by 16% year-over-year to $80 million, driven primarily by U.S. LINZESS collaboration revenue of $71 million.
Aerie Pharmaceuticals has generated first quarter 2020 net revenues of $20.3 million, with net cash used in operating activities for the quarter ended March 31, 2020 on a U.S. GAAP basis totaled approximately $41.8 million, resulting in $264.7 million in cash and cash equivalents and investments as of March 31, 2020.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the first quarter with strong sales of Captisol to partners evaluating remdesivir in multiple clinical trials and scaling-up for potential treatment courses for COVID-19
Atara reported net losses of $73.5 million, or $1.20 per share, for the first quarter of 2020 as compared to $66.3 million, or $1.44 per share, for the same period in 2019, with the total operating expenses include non-cash expenses of $14.5 million for the first quarter 2020, as compared to $13.9 million for the same period in 2019.
Rocket Pharmaceuticals has reported a strong balance sheet with $275.9 million in cash, capitalized into 2022.
PinCell has added new members to its management team and the board of directors following a successful seed funding led by Sofinnova Partners
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020, with minor impact from the Covid-19 pandemic seen to-date